Who needs more than two employees when artificial intelligence can do so many corporate tasks? It’s super efficient — and a little bit lonely.
Category: Drugs (Pharmaceuticals)
-
Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion
Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.
-
FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.’s Wishes
The peptides, which are increasingly marketed as providing longevity and health benefits, were removed in 2023 from the agency’s list of products that compounding pharmacies can sell.
-
How to Turn a Chicken Egg Into a Drug Factory
A biotech start-up is testing a novel way of efficiently producing pharmaceutical drugs.
-
Ozempic Is About to Go Generic in India, China and Canada
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
-
States Move to Limit Access to H.I.V. Treatment
Citing shortfalls in federal support, about 20 states are toughening eligibility requirements for patients in drug assistance programs.
-
Why Estrogen Patches For Menopause Are So Hard to Find
Changing attitudes around menopause treatment have driven up demand for hormone therapy.
-
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
-
Vaccine Makers Curtail Research and Cut Jobs
Federal policies under Robert F. Kennedy Jr. that are hostile to vaccines have “sent a chill through the entire industry,” one scientist said.
-
Should Drug Companies Be Advertising to Consumers?
Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are proposing bans.
-
U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine
The F.D.A.’s refusal to examine the company’s mRNA shot drew widespread criticism from doctors and was divisive within the agency.
-
Big Insurers Try to Shift Blame for High Health Costs to Hospitals and Drug Makers
At two congressional hearings, lawmakers slammed executives of major companies, saying they were failing to rein in the cost of medical care for consumers.